title: Difficulty in dislodging in vivo fixed radiostrontium.
abstract: Many trials based on the basic phenomena of isotopic dilution, adsorption, ion exchange, chelation, etc., have been attempted for the decorporation of radiostrontium, particularly Sr, after its entry in the in vivo system. We have recently demonstrated a non-isotopic carrier effect of some common calcium salts (calcium = 9 mg mL) to reduce the whole body retention of radiostrontium, if administered within 2 h after radiostrontium exposure and furthermore once daily, in rats, supplemented with calcium fortified diet. However, 25-30% of radiostrontium (compared to 50-60% in untreated animals) was still found to be retained in the animal even after 2 wk of treatment. Trial of some simple interventional measures, which would not adversely affect the animal metabolism, like pyrophosphate and magnesium sulfate, sodium citrate, chitin (a bio-absorbent), crown ether (a metal-chelator), and ammonium chloride, was therefore attempted to dislodge this remaining radiostrontium by switching over these animals to normal diet and subjecting them to different lines of treatment with these simple interventions through diet and drinking water separately for a further 4 wk. However, this remaining portion of radiostrontium is fixed in the bone and is difficult to dislodge.
authors.affiliation: Laboratory Nuclear Medicine Section (Isotope Group), c/o Tata Memorial Hospital Annexe, Parel. Mumbai, 400 012, India.
authors.forename: V R
authors.initials: VR
authors.lastname: Sonawane
authors.forename: V S
authors.initials: VS
authors.lastname: Jagtap
authors.forename: D N
authors.initials: DN
authors.lastname: Pahuja
authors.forename: M G R
authors.initials: MG
authors.lastname: Rajan
authors.forename: A M
authors.initials: AM
authors.lastname: Samuel
mesh_terms: D000042:Absorption; D000284:Administration, Oral; D000327:Adsorption; D000818:Animals; D000931:Antidotes / Q000008:administration & dosage; D001822:Body Burden; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism*; D002119:Calcium Carbonate / Q000008:administration & dosage; D017610:Calcium Compounds / Q000008:administration & dosage* / Q000493:pharmacokinetics; D002125:Calcium Gluconate / Q000008:administration & dosage; D002130:Calcium Phosphates / Q000008:administration & dosage; D002136:Calcium, Dietary / Q000008:administration & dosage* / Q000378:metabolism; D003666:Decontamination / Q000379:methods*; D004334:Drug Administration Schedule; D007274:Injections, Intraperitoneal; D007773:Lactates / Q000008:administration & dosage; D008657:Metabolic Clearance Rate / Q000187:drug effects; D009928:Organ Specificity; D011835:Radiation Protection / Q000379:methods*; D011837:Radiation-Protective Agents / Q000008:administration & dosage*; D051381:Rats; D017208:Rats, Wistar; D013326:Strontium Radioisotopes / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000633:toxicity; D014018:Tissue Distribution; D014915:Whole-Body Counting / Q000379:methods
chemical_list: D000931:Antidotes; D017610:Calcium Compounds; D002130:Calcium Phosphates; D002136:Calcium, Dietary; D007773:Lactates; D011837:Radiation-Protective Agents; D013326:Strontium Radioisotopes; C110051:calcium lactate; C020243:calcium phosphate; D002119:Calcium Carbonate; D002125:Calcium Gluconate